<DOC>
	<DOCNO>NCT02495662</DOCNO>
	<brief_summary>This study investigate liposomal prednisolone effective promote arteriovenous fistula ( AVF ) maturation administer human subject surgical creation radio-cephalic AVF .</brief_summary>
	<brief_title>The LIPMAT Study : Liposomal Prednisolone Improve Hemodialysis Fistula Maturation</brief_title>
	<detailed_description>AVFs prefer mean vascular access maintenance hemodialysis . Nonmaturation occur 30-50 % case , high rate radio-cephalic fistula . Inflammatory cytokine involve process nonmaturation . By suppress inflammation , corticosteroid might promote maturation , significant systemic side effect . Liposomal prednisolone long circulation time target inflame tissue low systemic concentration limited side effect . In animal study , demonstrate promote AVF maturation . At present , drug therapy aim improve shunt maturation available . This study investigate liposomal prednisolone effective promoting AVF maturation administer human subject surgical creation radio-cephalic AVF .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Neointima</mesh_term>
	<mesh_term>Vascular Remodeling</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Patients schedule creation radiocephalic AVF maintenance hemodialysis . 2 . Male female â‰¥ 18 year old . 3 . Patients able willing give write informed consent . 1 . Any concurrent illness , disability clinically significant abnormality may , judge investigator , affect interpretation clinical efficacy safety data prevent subject safely complete assessment require protocol . 2 . Current participation another interventional clinical trial subject receive investigational drug within 30 day prior baseline visit . 3 . History psychosis . 4 . History osteonecrosis 5 . Previous AVF ipsilateral arm . 6 . Current central venous catheter ipsilateral side . 7 . Treatment oral , rectal injectable ( include intraarticular ) glucocorticoid ( CS ) within 6 week prior baseline visit . Inhaled glucocorticoid allow . Topical steroid allow , however subject receive 100 gram mild moderate topical corticosteroid cream per week , 50 gram potent corticosteroid cream per week 30 gram potent topical corticosteroid cream per week 4 week prior baseline visit . 8 . Treatment immunosuppressant drug . Treatment nonsteroidal antiinflammatory drug ( NSAIDs ) . 9 . Patients unlikely adequately comply trial 's procedure ( due instance medical condition likely require extend interruption discontinuation , history substance abuse noncompliance ) . 10 . Women lactate , pregnant ( positive pregnancy test baseline ) planning become pregnant course study . 11 . Unwillingness use reliable acceptable contraceptive method throughout study till 3 month last study medication except female patient surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) least 1 year postmenopausal . 12 . Malignant disease , unless cure . Current prostate carcinoma without current plan cytostatic therapy allow . 13 . Uncontrolled Diabetes mellitus . 14 . Signs active infection , require systemic treatment . 15 . Positive Quantiferon test . 16 . Subject positive hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] , / antihepatitis B core antibody , / hepatitis C virus antibody [ antiHCV ] ) . 17 . History anaphylaxis severe allergic response , include radiocontrast agent . 18 . Planned livevirus vaccination . 19 . Planned surgical intervention plan elective hospital admission within 6 week AVF surgery . Planned hemodialysis session count exclusion criterion . 20 . Abnormal hepatic function ( Alanine aminotransferase ( ALT ) / aspartate aminotransferase ( AST ) bilirubin &gt; 2 x upper limit normal ) time screen visit . 21 . Clinically significant outofrange value hematology panel , discretion Principal Investigator . 22 . Current substance abuse alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Vascular access</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Arteriovenous shunt</keyword>
	<keyword>Arteriovenous fistula</keyword>
	<keyword>Maturation</keyword>
	<keyword>Liposomal prednisolone</keyword>
	<keyword>PEG-liposomal prednisolone sodium phosphate</keyword>
	<keyword>Radio-cephalic</keyword>
	<keyword>Shunt</keyword>
</DOC>